Japan's Ministry of Health, Labour and Welfare grants approval for Actelion's miglustat for the treatment of Niemann-Pick type C disease
Actelion Ltd announced that Japan's Ministry of Health, Labour and Welfare has granted approval for miglustat for the treatment of Niemann-Pick type C disease.
The approval was based on the data generated for the first approval of miglustat in this indication in the European Union, as well as data specifically generated for the submission to the Japanese Health Authorities.
Satoshi Tanaka, President of Actelion Japan and South Korea commented: "I am very proud to have achieved this successful approval. Our organization has been able to generate the additional clinical data required for the first approval of miglustat in Japan, successfully registered the drug in this orphan disease and we are looking forward to bringing the first therapy to patients with this devastating neurodegenerative disease."
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

How COVID-19 permanently damages the heart - Research team shows for the first time how the inflammation in COVID 19 alters the smallest vessels in the heart

Embryonic development and cancer cell growth - Embryonic factors for reprograming cancer cells

Chemotherapy or not? - Success in researching most effective methods for cancer therapy

Superdex™ 75 Increase, Superdex 200 Increase, Superose™ 6 Increase | Chromatography systems | Cytiva

New clues to the development of Parkinson's disease: Copper leads to protein aggregation - Suspicious metal
New treatment for a rare form of encephalitis
Researchers elucidate cause of death of photoreceptor cells in retinitis pigmentosa - Findings suggest new pathway as potential target for treatment of potentially blinding disease
QIAGEN Enables Efforts to Eradicate Costly Cattle Disease - Collaboration with Swiss laboratory Microsynth AG pioneers nucleic acid-based primary screening for Bovine Viral Diarrhea
New screening tool could speed development of ovarian cancer drugs
